pharma · Rheumatoid arthritis · Completely Resected Stage IIB, IIC, and III Melanoma
Celltrion Healthcare Australia
Celltrion Healthcare Australia Pty Ltd
Celltrion Healthcare Australia is a pharma organization headquartered in Sydney, AU. Primary therapeutic focus areas include Rheumatoid arthritis, Completely Resected Stage IIB, IIC, and III Melanoma, Previously Untreate
Sydney, AU HQ
9 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Sydney, AU
- Employees
- 9
- Programs
- 10
- Drugs
- 44
- Patents
- 0
CT-L03-301
Phase 3 · small molecule · Type 2 diabetes mellitus (T2DM)
CT-L03-301 for Type 2 diabetes mellitus (T2DM) is a Phase 3 program (small_molecule) at Celltrion Healthcare Australia Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code CT-L03-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Celltrion Healthcare Australia Pty Ltd
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Type 2 diabetes mellitus (T2DM)
- Status
- active
- Trials
- 1